Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
State-Of-The-Art in AML Therapy: FLT3, IDH1-2, CD33 & CD123, Venetoclax + Incorporation of Novel Anti-AML Targeted Therapies in 2020
Login to view comments.
Click here to Login
Malignant Hematology